Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study
Objectives: Therapeutic options in progressive forms of multiple sclerosis (MS) are still limited. Dimethyl fumarate (DMF) has immunomodulatory properties but may also exert antioxidative cytoprotective effects. Hence, it may be a therapeutic option for progressive MS. The aim of this observational...
Main Authors: | Katrin Strassburger-Krogias, Gisa Ellrichmann, Christos Krogias, Peter Altmeyer, Andrew Chan, Ralf Gold |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-09-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285614544466 |
Similar Items
-
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.
by: Gisa Ellrichmann, et al.
Published: (2011-01-01) -
Editorial: New Advances in Cerebrovascular Disorders
by: Theodoros Karapanayiotides, et al.
Published: (2023-09-01) -
Prognostic markers of post-stroke depression (PROMoSD): study protocol of a prospective single-center observational study on raphe hypoechogenicity as a predictor of post-stroke depression
by: Daniel Richter, et al.
Published: (2022-12-01) -
Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with Malignancy: A Systematic Review
by: Athina-Maria Aloizou, et al.
Published: (2022-08-01) -
Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
by: Maria Angela Samis Zella, et al.
Published: (2020-07-01)